How do TCR-Ts differ from CAR-T cell therapies?

T-cell receptor therapies (TCR-Ts) and chimeric antigen receptor T cell therapies (CAR-Ts) are created by engineering T cells. TCR-Ts are engineered to express a T-cell receptor that can recognise both extracellular and intracellular targets, including tumour-specific mutations expressed by cancer cells. CAR-Ts are genetically modified to express a chimeric antigen receptor that recognises a specific, cancer-associated protein on the surface of tumour cells.
We are advancing our diverse pipeline of innovative preclinical and clinical stage CAR-Ts and TCR-Ts across hard-to-treat tumours and malignancies.
Learn more about our ambition in cell therapy: www.astrazeneca.com/r-d/next-...
------------------------------------------------------------
Global site: www.astrazeneca.com/
Careers site: careers.astrazeneca.com/
Follow us:
Twitter: / astrazeneca
LinkedIn: / astrazeneca
Instagram: / astrazeneca
Facebook: / astrazeneca